small molecule

KLISYRI

TIRBANIBULIN

Loss of exclusivitySeptember 2038latest FDA-listed patent expiry

CompanyAlmirall →View the full company profile on CliffBio

Drug detail

Brand name	KLISYRI
Active ingredient	TIRBANIBULIN
Strength	1%
Dosage form	OINTMENT
Route	TOPICAL
Modality	Small molecule
FDA approval	December 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
10669236	September 2038	substance, product
10617693	March 2038	use U-3015
11497750	March 2038	use U-3015
7300931	December 2030	substance, product
7851470	February 2029	substance, product
10323001	December 2027	product

Regulatory exclusivity

Code	Expires
D-192	June 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Almirall